Références

  1. National Institute for Health and Care Excellence (NICE). Breast cancer: Quality Standard QS12. NICE. 2016. Available at: https://www.nice.org.uk/guidance/qs12. Accessed May 2025.
  2. Cancer Research UK. Why is early diagnosis important? Cancer Research UK. 2023. Available at: https://www.cancerresearchuk.org/about-cancer/spot-cancer-early/why-is-early-diagnosis-important. Accessed May 2025.
  3. World Cancer Research Fund International. Breast cancer statistics. London, UK: WCRF International. 2024. Available at: https://www.wcrf.org/preventing-cancer/cancer-statistics/breast-cancer-statistics/. Accessed May 2025.
  4. World Health Organization. Global cancer burden growing amidst mounting need for services. Geneva, Switzerland: WHO. 2024. Available at: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services. Accessed May 2025.
  5. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.
  6. Kim J, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154–1162.
  7. Wang L. Early Diagnosis of Breast Cancer. Sensors. 2017;17:1572.
  8. Wang X, et al. Avoidable and unavoidable repeat breast core needle biopsies. Arch Breast Cancer. 2022;9:32–39.
  9. Shaaban AM, et al. Management of B3 Lesions-Practical issues. Curr Breast Cancer Rep. 2019;11:83–88.
  10. Zhang Y, et al. The comparison of efficacy and safety evaluation of vacuum-assisted Elite 10-G system and the traditional BARD 14-G core needle in breast diagnosis: an open-label, parallel, randomized controlled trial. Int J Surg. 2023;109(5):1180–1187.
  11. O'Flynn EA, et al. Image-guided breast biopsy: state-of-the-art. Clin Radiol. 2010;65(4):259–270.
  12. Philpotts LE, et al. Comparison of rebiopsy rates after stereotactic core needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle and automatic gun. AJR Am J Roentgenol.1999;172(3):683–687.
  13. Szynglarewicz B, et al. Pain experienced by patients during minimal-invasive ultrasound-guided breast biopsy: vacuum-assisted vs core-needle procedure. Eur J Surg Oncol. 2011;37(5):398–403.
  14. van de Voort EMF, et al. Implementation of vacuum-assisted excision as a management option for benign and high-risk breast lesions. Br J Radiol. 2023;96(1147);20220776.
  15. Salazar JP, et al. Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes. Br J Radiol. 2019; 921(1094);20180626.
  16. Gil MLBV, et al. Vacuum-assisted excision: A safe minimally invasive option for benign phyllodes tumor diagnosis and treatment-a systematic review and meta-analysis. Front Oncol. 2024;14:1394116.
  17. Yoo H-S, et al. Efficacy and safety of vacuum-assisted excision for benign breast mass lesion: A meta-analysis. Medicina. 2021;57:1260.
  18. Perretta T, et al. Evaluation of ultrasound-guided 8-gauge vacuum-assisted excision system for the removal of US-detectable breast lesions. Anticancer Res. 2020;40:1719-1729.
  19. Ko EY, et al. Factors affecting the efficacy of ultrasound-guided vacuum-assisted percutaneous excision for removal of benign breast lesions. J Ultrasound Med. 2008; 27:65-73.
  20. Sharma N, et al. impact of vacuum-assisted excision in the management of indeterminate B3 lesions in the NHS Breast Screening Programme in England. Clin Radiol. 2021;470.e23-470.e29.
  21. Martin EA, et al. Current status of biopsy markers for the breast in clinical settings. Expert Rev Med Devices. 2022;19(12):965-975.
  22. Shah AD, et al. Breast tissue markers: Why? What's out there? How do I choose?. Clin Imaging. 2018;52:123-136.
  23. Alshafeiy TI, et al. Advantages and challenges of Using breast biopsy markers. J Breast Imaging. 2022;4(1):78-95.
  24. Harvey JA. To Place a Breast Biopsy Marker or Not? J Breast Imaging. 2022;4(3):229-230.

Rejoignez-nous et commencez votre parcours vers l’excellence diagnostique

Ne manquez pas cette occasion ! Acceptez de recevoir des communications et bénéficiez d’un accès exclusif aux données cliniques, aux événements spéciaux et au contenu conçu uniquement pour notre communauté dédiée à la santé de la femme.